T cell receptor gamma variable B (pseudogene)Genealiases: TCRGVB · V6P
Q-omics provides the consensus-scored TRGVB profile across patient tissues and cancer cell-line models. TRGVB expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TRGVB is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRGVB RNA expression shows 6,418 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, KIRC, and STAD as cancer lineages where TRGVB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGVB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGVB survival associations across molecular data types. TRGVB RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGVB RNA expression–survival associations across cancer types. High TRGVB expression shows unfavorable associations in UCS, LUSC, TGCT and READ, but favorable associations in LAML and CHOL. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for TRGVB RNA expression.
This table summarizes TRGVB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRGVB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGVB shows higher tumor expression in KIRC, PRAD, HNSC and KIRP. The KIRC box plot shows higher TRGVB RNA expression in tumor versus normal tissue (log2 FC = +0.085, t-test p = .001).
This table shows molecular features associated with TRGVB in patient tissues and cancer cell lines. In patient samples, TRGVB shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
